Proteome Sciences plc
PRM.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.05 | -0.06 | -0.01 |
| FCF Yield | -10.61% | -5.20% | -4.98% | -79,860.71% |
| EV / EBITDA | -19.98 | -98.06 | -17.96 | -19.67 |
| Quality | ||||
| ROIC | -23.07% | -8.33% | -20.02% | -13.42% |
| Gross Margin | -4.85% | 2.17% | 27.60% | -694,329.48% |
| Cash Conversion Ratio | 0.42 | 0.26 | 0.23 | 9,609.65 |
| Growth | ||||
| Revenue 3-Year CAGR | -93.97% | -29.97% | -14.05% | -2.72% |
| Free Cash Flow Growth | -81.21% | -0.76% | 100.00% | -171.23% |
| Safety | ||||
| Net Debt / EBITDA | -12.52 | -55.81 | -9.73 | -9.07 |
| Interest Coverage | -3.60 | -1.43 | -3.86 | -3.53 |
| Efficiency | ||||
| Inventory Turnover | 3.97 | 3.57 | 2.08 | 2.32 |
| Cash Conversion Cycle | 18.53 | 20.36 | 30.89 | 70.00 |